BACKGROUND: As therapy for non-small-cell lung cancer (NSCLC) patients becomes more personalized, additional tissue in the form of core-needle biopsies (CNBs) for biomarker analysis is increasingly required for determining appropriate treatment and for enrollment into clinical trials. We report our experience with small-caliber percutaneous transthoracic (PT) CNBs for the evaluation of multiple molecular biomarkers in BATTLE (biomarker-integrated approaches of targeted therapy for lung cancer elimination), a personalized, targeted therapy NSCLC clinical trial. METHODS: The medical records of patients who underwent PTCNB for consideration of enrollment in BATTLE were reviewed for diagnostic yield of 11 predetermined molecular markers and procedural complications. Univariate and multivariate analyses of factors related to patient and lesion characteristics were performed to determine possible influences on diagnostic yield. RESULTS: One hundred and seventy PTCNBs were performed using 20-gauge biopsy needles in 151 NSCLC patients screened for the trial. The biopsy specimens of 82.9% of the patients were found to have adequate tumor tissue for analysis of the required biomarkers. On multivariate analysis, metastatic lesions were 5.4 times more likely to yield diagnostic tissue as compared with primary tumors (p = 0.0079). Pneumothorax and chest tube insertion rates were 15.3% and 9.4%, respectively. CONCLUSIONS: Image-guided 20-gauge PTCNB is safe and provides adequate tissue for analysis of multiple biomarkers in the majority of patients being considered for enrollment into a personalized, targeted therapy NSCLC clinical trial. Metastatic lesions are more likely to yield diagnostic tissue as compared with primary tumors.
BACKGROUND: As therapy for non-small-cell lung cancer (NSCLC) patients becomes more personalized, additional tissue in the form of core-needle biopsies (CNBs) for biomarker analysis is increasingly required for determining appropriate treatment and for enrollment into clinical trials. We report our experience with small-caliber percutaneous transthoracic (PT) CNBs for the evaluation of multiple molecular biomarkers in BATTLE (biomarker-integrated approaches of targeted therapy for lung cancer elimination), a personalized, targeted therapy NSCLC clinical trial. METHODS: The medical records of patients who underwent PTCNB for consideration of enrollment in BATTLE were reviewed for diagnostic yield of 11 predetermined molecular markers and procedural complications. Univariate and multivariate analyses of factors related to patient and lesion characteristics were performed to determine possible influences on diagnostic yield. RESULTS: One hundred and seventy PTCNBs were performed using 20-gauge biopsy needles in 151 NSCLCpatients screened for the trial. The biopsy specimens of 82.9% of the patients were found to have adequate tumor tissue for analysis of the required biomarkers. On multivariate analysis, metastatic lesions were 5.4 times more likely to yield diagnostic tissue as compared with primary tumors (p = 0.0079). Pneumothorax and chest tube insertion rates were 15.3% and 9.4%, respectively. CONCLUSIONS: Image-guided 20-gauge PTCNB is safe and provides adequate tissue for analysis of multiple biomarkers in the majority of patients being considered for enrollment into a personalized, targeted therapy NSCLC clinical trial. Metastatic lesions are more likely to yield diagnostic tissue as compared with primary tumors.
Authors: J F Silverman; J L Finley; K F O'Brien; D J Dabbs; H K Park; E W Larkin; H T Norris Journal: Acta Cytol Date: 1989 Nov-Dec Impact factor: 2.319
Authors: Servet Tatli; Victor H Gerbaudo; Christina M Feeley; Paul B Shyn; Kemal Tuncali; Stuart G Silverman Journal: J Vasc Interv Radiol Date: 2011-03-02 Impact factor: 3.464
Authors: Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Wilbur A Franklin; Rafal Dziadziuszko; Nick Thatcher; Alex Chang; Purvish Parikh; José Rodrigues Pereira; Tudor Ciuleanu; Joachim von Pawel; Claire Watkins; Angela Flannery; Gillian Ellison; Emma Donald; Lucy Knight; Dinah Parums; Nicholas Botwood; Brian Holloway Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: I Zudaire; M D Lozano; M F Vazquez; M J Pajares; J Agorreta; R Pio; J J Zulueta; D F Yankelevitz; C I Henschke; L M Montuenga Journal: Histol Histopathol Date: 2008-01 Impact factor: 2.303
Authors: Anne M Covey; Ripal Gandhi; Lynn A Brody; George Getrajdman; Howard T Thaler; Karen T Brown Journal: J Vasc Interv Radiol Date: 2004-05 Impact factor: 3.464
Authors: S Savic; C Tapia; B Grilli; A Rufle; M P Bihl; A de Vito Barascud; M Herzog; L Terracciano; F Baty; L Bubendorf Journal: Br J Cancer Date: 2007-12-18 Impact factor: 7.640
Authors: Alda L Tam; Howard J Lim; Ignacio I Wistuba; Anobel Tamrazi; Michael D Kuo; Etay Ziv; Stephen Wong; Albert J Shih; Robert J Webster; Gregory S Fischer; Sunitha Nagrath; Suzanne E Davis; Sarah B White; Kamran Ahrar Journal: J Vasc Interv Radiol Date: 2015-11-25 Impact factor: 3.464
Authors: Erik Folch; Norihiro Yamaguchi; Paul A VanderLaan; Olivier N Kocher; David H Boucher; Michael A Goldstein; Mark S Huberman; Michael S Kent; Sidharta P Gangadharan; Daniel B Costa; Adnan Majid Journal: J Thorac Oncol Date: 2013-11 Impact factor: 15.609
Authors: C Lim; H S Sekhon; J C Cutz; D M Hwang; S Kamel-Reid; R F Carter; G da Cunha Santos; T Waddell; M Binnie; M Patel; N Paul; T Chung; A Brade; R El-Maraghi; C Sit; M S Tsao; N B Leighl Journal: Curr Oncol Date: 2017-04-27 Impact factor: 3.677
Authors: Elliot B Levy; Maria I Fiel; Stanley R Hamilton; David E Kleiner; Shannon J McCall; Peter Schirmacher; William Travis; Michael D Kuo; Robert D Suh; Alda L Tam; Shaheen U Islam; Katherine Ferry-Galow; Rebecca A Enos; James H Doroshow; Hala R Makhlouf Journal: J Clin Oncol Date: 2020-03-05 Impact factor: 44.544
Authors: Vassiliki Papadimitrakopoulou; J Jack Lee; Ignacio I Wistuba; Anne S Tsao; Frank V Fossella; Neda Kalhor; Sanjay Gupta; Lauren Averett Byers; Julie G Izzo; Scott N Gettinger; Sarah B Goldberg; Ximing Tang; Vincent A Miller; Ferdinandos Skoulidis; Don L Gibbons; Li Shen; Caimiao Wei; Lixia Diao; S Andrew Peng; Jing Wang; Alda L Tam; Kevin R Coombes; Ja Seok Koo; David J Mauro; Eric H Rubin; John V Heymach; Waun Ki Hong; Roy S Herbst Journal: J Clin Oncol Date: 2016-10-20 Impact factor: 44.544
Authors: Marvaretta Stevenson; Jared Christensen; Debra Shoemaker; Traci Foster; William T Barry; Betty C Tong; Momen Wahidi; Scott Shofer; Michael Datto; Geoffrey Ginsburg; Jeffrey Crawford; Thomas D'Amico; Neal Ready Journal: Cancer Invest Date: 2014-05-09 Impact factor: 2.176
Authors: Katherine V Ferry-Galow; Vivekananda Datta; Hala R Makhlouf; John Wright; Bradford J Wood; Elliot Levy; Etta D Pisano; Alda L Tam; Susanna I Lee; Umar Mahmood; Lawrence V Rubinstein; James H Doroshow; Alice P Chen Journal: J Oncol Pract Date: 2018-10-04 Impact factor: 3.840
Authors: Judy U Ahrar; Sanjay Gupta; Joe E Ensor; Armeen Mahvash; Sharjeel H Sabir; Joseph R Steele; Stephen E McRae; Rony Avritscher; Steven Y Huang; Bruno C Odisio; Ravi Murthy; Kamran Ahrar; Michael J Wallace; Alda L Tam Journal: Cardiovasc Intervent Radiol Date: 2016-11-08 Impact factor: 2.740